InvestorsHub Logo
Followers 4
Posts 682
Boards Moderated 0
Alias Born 06/26/2013

Re: None

Tuesday, 09/20/2022 9:27:55 AM

Tuesday, September 20, 2022 9:27:55 AM

Post# of 547
MYMD-1 moves on to cohort 3, 900 mg level, in phase 2 life extension study with no problems so far, and expects efficacy data in 4th quarter 2022!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MYMD News